Daré Bioscience Statistics
Total Valuation
Daré Bioscience has a market cap or net worth of $28.34 million. The enterprise value is $26.33 million.
Important Dates
The last earnings date was Thursday, August 14, 2025, after market close.
Earnings Date | Aug 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Daré Bioscience has 13.18 million shares outstanding. The number of shares has increased by 10.12% in one year.
Current Share Class | 13.18M |
Shares Outstanding | 13.18M |
Shares Change (YoY) | +10.12% |
Shares Change (QoQ) | +1.28% |
Owned by Insiders (%) | 1.05% |
Owned by Institutions (%) | 6.86% |
Float | 13.04M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | -1,600.81 |
Forward PS | 2.93 |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.34
Current Ratio | 0.34 |
Quick Ratio | 0.27 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -63.13% |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | 296.05% |
Revenue Per Employee | n/a |
Profits Per Employee | -$808,856 |
Employee Count | 23 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.11% in the last 52 weeks. The beta is 1.14, so Daré Bioscience's price volatility has been higher than the market average.
Beta (5Y) | 1.14 |
52-Week Price Change | -40.11% |
50-Day Moving Average | 2.32 |
200-Day Moving Average | 2.88 |
Relative Strength Index (RSI) | 48.66 |
Average Volume (20 Days) | 182,162 |
Short Selling Information
The latest short interest is 261,127, so 1.98% of the outstanding shares have been sold short.
Short Interest | 261,127 |
Short Previous Month | 229,708 |
Short % of Shares Out | 1.98% |
Short % of Float | 2.00% |
Short Ratio (days to cover) | 0.41 |
Income Statement
In the last 12 months, Daré Bioscience had revenue of -$17,701 and -$18.60 million in losses. Loss per share was -$2.14.
Revenue | -17,701 |
Gross Profit | -14.32M |
Operating Income | -18.48M |
Pretax Income | -28.87M |
Net Income | -18.60M |
EBITDA | -17.84M |
EBIT | -18.48M |
Loss Per Share | -$2.14 |
Full Income Statement Balance Sheet
The company has $5.04 million in cash and $3.03 million in debt, giving a net cash position of $2.00 million or $0.15 per share.
Cash & Cash Equivalents | 5.04M |
Total Debt | 3.03M |
Net Cash | 2.00M |
Net Cash Per Share | $0.15 |
Equity (Book Value) | -12.73M |
Book Value Per Share | -1.41 |
Working Capital | -12.62M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$11.59 million and capital expenditures -$284,459, giving a free cash flow of -$11.87 million.
Operating Cash Flow | -11.59M |
Capital Expenditures | -284,459 |
Free Cash Flow | -11.87M |
FCF Per Share | -$0.90 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | 104,392.20% |
Pretax Margin | 105,099.65% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Daré Bioscience does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -10.12% |
Shareholder Yield | -10.12% |
Earnings Yield | -65.65% |
FCF Yield | -41.89% |
Analyst Forecast
The average price target for Daré Bioscience is $10.00, which is 365.12% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $10.00 |
Price Target Difference | 365.12% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | 681.78% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2024. It was a reverse split with a ratio of 1:12.
Last Split Date | Jul 1, 2024 |
Split Type | Reverse |
Split Ratio | 1:12 |
Scores
Daré Bioscience has an Altman Z-Score of -25.03 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -25.03 |
Piotroski F-Score | 2 |